Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice

Vaccine

Volumn 24, Issue 23, 2006, Pages 4987-4994

  Taylor, Jennifer M ^a   Ziman, Melanie E ^a   Huff, Jennifer L ^a   Moroski, Nathan M ^a   Vajdy, Michael ^a   Solnick, Jay V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Helicobacter pylori; LPS; Mucosal immunity; Th1 immunity

Indexed keywords

CHOLERA TOXIN; GAMMA INTERFERON; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STATISTICAL SIGNIFICANCE; TH1 CELL; TH2 CELL; TITRIMETRY;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CYTOKINES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS;

EID: 33646862984     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.043     Document Type: Article

References (46)

1. Suerbaum S., and Michetti P. Helicobacter pylori infection. N Engl J Med 347 15 (2002) 1175-1186
2. Del Giudice G., Covacci A., Telford J.L., Montecucco C., and Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19 (2001) 523-563
3. Peek Jr. R.M., and Blaser M.J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2 1 (2002) 28-37
4. Lucey D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 4 (1996) 532-562
5. Lundgren A., Trollmo C., Edebo A., Svennerholm A.M., and Lundin B.S. Helicobacter pylori-specific CD4(+) T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun 73 9 (2005) 5612-5619
6. Louis E., Franchimont D., Piron A., et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113 3 (1998) 401-406
7. Yamamoto T., Kita M., Ohno T., Iwakura Y., Sekikawa K., and Imanishi J. Role of tumor necrosis factor-alpha and interferon-gamma in Helicobacter pylori infection. Microbiol Immunol 48 9 (2004) 647-654
8. Akhiani A.A., Pappo J., Kabok Z., et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169 12 (2002) 6977-6984
9. Garhart C.A., Nedrud J.G., Heinzel F.P., Sigmund N.E., and Czinn S.J. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect Immun 71 6 (2003) 3628-3633
10. Kamradt A.E., Greiner M., Ghiara P., and Kaufmann S.H. Helicobacter pylori infection in wild-type and cytokine-deficient C57BL/6 and BALB/c mouse mutants. Microb Infect 2 6 (2000) 593-597
11. Kambayashi T., Assarsson E., Lukacher A.E., Ljunggren H.G., and Jensen P.E. Memory CD8+ T cells provide an early source of IFN-gamma. J Immunol 170 5 (2003) 2399-2408
12. Raue H.P., Brien J.D., Hammarlund E., and Slifka M.K. Activation of virus-specific CD8+ T cells by lipopolysaccharide-induced IL-12 and IL-18. J Immunol 173 11 (2004) 6873-6881
13. Ethuin F., Gerard B., Benna J.E., et al. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab Invest 84 10 (2004) 1363-1371
14. Gould M.P., Greene J.A., Bhoj V., DeVecchio J.L., and Heinzel F.P. Distinct modulatory effects of LPS and CpG on IL-18-dependent IFN-gamma synthesis. J Immunol 172 3 (2004) 1754-1762
15. Kariminia A., Kavoossy G., Khatami S., Zowghi E., and Ardestani S.K. Study of interleukin-10 and interleukin-12 productions in response to lipopolysaccharides extracted from two different Brucella strains. Comp Immunol Microbiol Infect Dis 25 2 (2002) 85-93
16. Birkholz S., Knipp U., Nietzki C., Adamek R.J., and Opferkuch W. Immunological activity of lipopolysaccharide of Helicobacter pylori on human peripheral mononuclear blood cells in comparison to lipopolysaccharides of other intestinal bacteria. FEMS Immunol Med Microbiol 6 4 (1993) 317-324
17. Nielsen H., Birkholz S., Andersen L.P., and Moran A.P. Neutrophil activation by Helicobacter pylori lipopolysaccharides. J Infect Dis 170 1 (1994) 135-139
18. Ogawa T., Suda Y., Kashihara W., et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine 15 15 (1997) 1598-1605
19. Eaton K.A., Logan S.M., Baker P.E., Peterson R.A., Monteiro M.A., and Altman E. Helicobacter pylori with a truncated lipopolysaccharide O chain fails to induce gastritis in SCID mice injected with splenocytes from wild-type C57BL/6J mice. Infect Immun 72 7 (2004) 3925-3931
20. Mandell L., Moran A.P., Cocchiarella A., et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 72 11 (2004) 6446-6454
21. Zambon C.F., Basso D., Navaglia F., et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 29 4 (2005) 141-152
22. Satin B., Del Giudice G., Della Bianca V., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 191 9 (2000) 1467-1476
23. Weltzin R., Guy B., Thomas Jr. W.D., Giannasca P.J., and Monath T.P. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 68 5 (2000) 2775-2782
24. Vajdy M., Singh M., Ugozzoli M., et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 110 1 (2003) 86-94
25. Guadalupe M., Reay E., Sankaran S., et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77 21 (2003) 11708-11717
26. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 5396 (1998) 2085-2088
27. Qureshi S.T., Lariviere L., Leveque G., et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189 4 (1999) 615-625
28. Hasunuma R., Morita H., Tanaka S., et al. Differential clearance and induction of host responses by various administered or released lipopolysaccharides. J Endotoxin Res 7 6 (2001) 421-429
29. Fitzgerald K.A., Rowe D.C., and Golenbock D.T. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microb Infect 6 15 (2004) 1361-1367
30. Muotiala A., Helander I.M., Pyhala L., Kosunen T.U., and Moran A.P. Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun 60 4 (1992) 1714-1716
31. Moran A.P., Lindner B., and Walsh E.J. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides. J Bacteriol 179 20 (1997) 6453-6463
32. Bliss Jr. C.M., Golenbock D.T., Keates S., Linevsky J.K., and Kelly C.P. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun 66 11 (1998) 5357-5363
33. Moran A.P., Helander I.M., and Kosunen T.U. Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. J Bacteriol 174 4 (1992) 1370-1377
34. Rad R., Dossumbekova A., Neu B., et al. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 53 8 (2004) 1082-1089
35. Perez-Perez G.I., Shepherd V.L., Morrow J.D., and Blaser M.J. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 63 4 (1995) 1183-1187
36. Monteiro M.A., Appelmelk B.J., Rasko D.A., et al. Lipopolysaccharide structures of Helicobacter pylori genomic strains 26695 and J99, mouse model H. pylori Sydney strain, H. pylori P466 carrying sialyl Lewis X, and H. pylori UA915 expressing Lewis B classification of H. pylori lipopolysaccharides into glycotype families. Eur J Biochem 267 2 (2000) 305-320
37. Padol I.T., Moran A.P., and Hunt R.H. Effect of purified lipopolysaccharides from strains of Helicobacter pylori and Helicobacter felis on acid secretion in mouse gastric glands in vitro. Infect Immun 69 6 (2001) 3891-3896
38. D'Elios M.M., Appelmelk B.J., Amedei A., Bergman M.P., and Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 10 7 (2004) 316-323
39. Moran A.P., and Prendergast M.M. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun 16 3 (2001) 241-256
40. Rudnicka W., Jarosinska A., Bak-Romaniszyn L., et al. Helicobacter pylori lipopolysaccharide in the IL-2 milieu activates lymphocytes from dyspeptic children. FEMS Immunol Med Microbiol 36 3 (2003) 141-145
41. Piotrowski J., Piotrowski E., Skrodzka D., Slomiany A., and Slomiany B.L. Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide. Scand J Gastroenterol 32 3 (1997) 203-211
42. Sakagami T., Vella J., Dixon M.F., et al. The endotoxin of Helicobacter pylori is a modulator of host-dependent gastritis. Infect Immun 65 8 (1997) 3310-3316
43. Sutton P., Wilson J., and Lee A. Further development of the Helicobacter pylori mouse vaccination model. Vaccine 18 24 (2000) 2677-2685
44. Raghavan S., Hjulstrom M., Holmgren J., and Svennerholm A.M. Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect Immun 70 11 (2002) 6383-6388
45. Keenan J.I., Rijpkema S.G., Durrani Z., and Roake J.A. Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens. FEMS Immunol Med Microbiol 36 3 (2003) 199-205
46. Shi T., Liu W.Z., Gao F., Shi G.Y., and Xiao S.D. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter 10 1 (2005) 71-79